早期应用尼麦角林治疗急性脑梗死的临床观察

Clinical Observation of Nicergoline in Treatment of Acute Cerebral Infraction During the Early Period

目的探讨早期应用尼麦角林对急性脑梗死的有效性及安全性。方法选取80例急性脑梗死患者随机分为尼麦角林治疗组(n=40)和常规治疗组(n=40)。常规治疗组按常规方法治疗,尼麦角林治疗组在常规治疗的同时加用尼麦角林8mg静滴,1/d,连续应用10d。对两组患者治疗前后欧洲卒中评分(ESS评分)、日常生活能力评分(Bar-thel指数)及临床疗效进行综合比较。结果尼麦角林治疗组治疗后ESS评分、Barthel指数均显著高于常规治疗组(P<0.05);尼麦角林治疗组临床疗效明显优于常规治疗组(P<0.05)。结论尼麦角林可改善急性脑梗死患者神经功能缺损及日常生活能力,疗效显著且无明显副作用,可安全应用于临床。

Objective To testify the efficacy and safety of nicergoline in treatment of acute cerebral infarction （ACI） in the early period. Methods Altogether 80 patients with ACI were randomly divided into the nicergoline group （n = 40） and the conventional therapy control group （n = 40）. Conventional therapy and care were used in the control group. In the nicergoline group, patients were received additional nicergoline injection at doses of 8mg diluted with 250mL saline solution IV infusion once daily for 10 successive days along with the conventional remedy. The changes of ESS, Barthel index, and clinical improvement were monitored and accessed. Results Significant differences of the changes of ESS value and Barthel index were observed between the nicergoline group and the control group （P〈 0.05）. The total effective rate was significantly higher in the nicergoline group （P〈 0.05）. Conclusions Nicergoline could reduce the nerve function deterioration grade and improve the life quality of ACI patients. Nicergoline is a safe and effective drug in treatment of ACI.